AGA technical review on nonalcoholic fatty liver disease

Gastroenterology

Volumn 123, Issue 5, 2002, Pages 1705-1725

  Sanyal, Arun J ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTILIPEMIC AGENT; BETA CAROTENE; BETAINE; BIGUANIDE DERIVATIVE; GEMFIBROZIL; METFORMIN; PHOSPHATIDYLCHOLINE; PIOGLITAZONE; ROSIGLITAZONE; SELENIUM; TAURINE; TROGLITAZONE; URSODEOXYCHOLIC ACID;

CLINICAL TRIAL; DISEASE COURSE; FATTY LIVER; HEPATITIS; HISTOLOGY; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER PROTECTION; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 0036829092     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1053/gast.2002.36572     Document Type: Article

References (280)

1. American Gastroenterological Association. Position and policy statement: Policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995;108:925-926.
2. Gross PA, Barrett TL, Dellinger EP, Krause PJ, Martone WJ, McGowan JE Jr, Sweet RL, Wenzel RP. Purpose of quality standards for infectious diseases. Infectious Diseases Society of America. Clin Infect Dis 1994;18:421.
3. NHS Center for Reviews and Dissemination: Undertaking Systematic Reviews of Research on Effectiveness: CRD Guidelines for those Carrying Out or Commissioning Reviews. CRD report #4. York: University of York, 1996.
4. Zelman S. The liver in obesity. Arch Intern Med 1958;90:141-156.
5. Payne JH, Dewind LT, Commons RR. Metabolic observations in patients with jejunocolic shunts. Am J Surg 1963;106:273-289.
6. Catlin R. Liver dysfunction after intestinal bypass. JAMA 1963;185:1693-1694.
7. McGill DB, Humpherys SR, Baggenstoss AH, Dickson ER. Cirrhosis and death afterjejunoileal shunt. Gastroenterology 1972;63:872-877.
8. Peters RL, Gay T, Reynolds TB. Post-jejuno-ileal bypass hepatic disease. Its similarity to alcoholic liver disease. Am J Clin Pathol 1975;63:318-331.
9. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816.
10. Thaler H. Relation of steatosis to cirrhosis. Clin Gastroenterol 1975;4:273-280.
11. Nasrallah SM, Wills CE Jr, Galambos JT. Hepatic morphology in obesity. Dig Dis Sci 1981;26:325-327.
12. Itoh S, Tsukada Y, Motomura Y, Ichinoe A. Five patients with nonalcoholic diabetic cirrhosis. Acta Hepatogastroenterol Stuttg 1979;26:90-97.
13. Falchuk KR, Fiske SC, Haggitt RC, Federman M, Trey C. Pericentral hepatic fibrosis and intracellular hyalin in diabetes mellitus. Gastroenterology 1980;78:535-541.
14. Hornboll P, Olsen TS. Fatty changes in the liver: The relation to age, overweight and diabetes mellitus. Acta Pathol Microbiol Immunol Scand A 1982;90:199-205.
15. Ludwig J, Viggiano TR, McGill DB, Oh BJ. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 1980;55:434-438.
16. Baker AL. Nonalcoholic steatonecrosis: A unique histopathologic lesion of the liver with multiple causes. Surv Dig Dis 1985;3:154-164.
17. French SW, Eidus LB, Freeman J. Nonalcoholic fatty hepatitis: An important clinical condition. Can J Gastroenterol 1989;3:189-197.
18. Lee RG. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler. Hepatology 1995;21:1742-1743.
19. Galambos JT, Wills CE. Relationship between 505 paired liver tests and biopsies in 242 obese patients. Gastroenterology 1978;74:1191-1195.
20. Nagore N, Scheur PJ. The pathology of diabetic hepatitis. J Pathol 1988;156:155-160.
21. Hall PD. Pathological spectrum of alcoholic liver disease. Alcohol Alcohol Suppl 1994;2:303-313.
22. Bacon BR, Farahvash MJ, Janney CG, Neuschwander Tetri BA. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994;107:1103-1109.
23. Christoffersen P, Petersen P. Morphological features in non-cirrhotic livers from patients with chronic alcoholism, diabetes mellitus or adipositas. A comparative study. Acta Pathol Microbiol Scand A 1978;86A:495-498.
24. Gluud C, Christoffersen P, Andersen T, Morton JA, McGee JO. Occurrence and significance of Mallory bodies in morbidly obese patients. An immunohistochemical study. Acta Pathol Microbiol Immunol Scand A 1984;92:39-43.
25. Younossi ZM, Boparai N. Agreement in pathologic interpretation of liver biopsy specimens in posttransplant hepatitis C infection. Arch Pathol Lab Med 1999;123:143-145.
26. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
27. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: A proposal for grading and staging the histological lesions. Am J Gastroenterol 1999;94:2467-2474.
28. Anderson T, Christoffersen P, Gluud C. The liver in consecutive patients with morbid obesity: A clinical morphological and biochemical study. Int J Obes 1984;8:107-115.
29. Teli MR, James OF, Burt AD, Bennett MK, Day CP. The natural history of nonalcoholic fatty liver: A follow-up study. Hepatology 1995;22:1714-1719.
30. Franzese A, Vajro P, Argenziano A, Puzziello A, Iannucci MP, Saviano MC, Brunetti F, Rubino A. Liver involvement in obese children. Ultrasonography and liver enzyme levels at diagnosis and during follow-up in an Italian population. Dig Dis Sci 1997;42:1428-1432.
31. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Tani S, Goto M. Prevalence of fatty liver in a general population of Okinawa, Japan. Jpn J Med 1988;27:142-149.
32. Kawasaki T, Hashimoto N, Kikuchi T, Takahashi H, Uchiyama M. The relationship between fatty liver and hyperinsulinemia in obese Japanese children. J Pediatr Gastroenterol Nutr 1997;24:317-321.
33. Tazawa Y, Noguchi H, Nishinomiya F, Takada G. Serum alanine aminotransferase activity in obese children. Acta Paediatr 1997;86:238-241.
34. Ikai E, Ishizaki M, Suzuki Y, Ishida M, Noborizaka Y, Yamada Y. Association between hepatic steatosis, insulin resistance and hyperinsulinaemia as related to hypertension in alcohol consumers and obese people. J Hum Hypertens 1995;9:101-105.
35. Marcos A, Fisher RA, Ham JM, Olzinski AT, Shiffman ML, Sanyal AJ, Luketic VA, Sterling RK, Olbrisch ME, Posner MP. Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000;69:2410-2415.
36. Ground KEV. Prevalence of fatty liver in healthy adults accidentally killed. Aviat Space Environ Med 1984;55:59-61.
37. Wanless IR, Lentz JS. Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factors. Hepatology 1990;11:74-80.
38. Tominaga K, Kurata JH, Chen YK, Fujimoto E, Miyagawa S, Abe I, Kusano Y. Prevalence of fatty liver in Japanese children and relationship to obesity. An epidemiological ultrasonographic survey. Dig Dis Sci 1995;40:2002-2009.
39. Noguchi H, Tazawa Y, Nishinomiya F, Takada G. The relationship between serum transaminase activities and fatty liver in children with simple obesity. Acta Paediatr Jpn 1995;37:621-625.
40. Nomura F, Ohnishi K, Satomura Y. Liver function in moderate obesity: Study in 535 moderately obese subjects among 4613 male company employees. Int J Obes 1986;10:349-354.
41. Anderson T, Gluud C. Liver morphology in morbid obesity: A literature study. Int J Obes 1984;8:97-106.
42. Bellentani S, Saccoccio G, Masutti F, Croce LS, Brandi G, Sasso F, Cristanini G, Tiribelli C. Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 2000;132:112-117.
43. Kinugasa A, Tsunamoto K, Furukawa N, Sawada T, Kusunoki T, Shimada N. Fatty liver and its fibrous changes found in simple obesity of children. J Pediatr Gastroenterol Nutr 1984;3:408-414.
44. Popkin BM, Udry JR. Adolescent obesity increases significantly in second and third generation U.S. immigrants: The National Longitudinal Study of Adolescent Health. J Nutr 1998;128:701-706.
45. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: Prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
46. Johnson-Down L, O'Loughlin J, Koski KG, Gray-Donald K. High prevalence of obesity in low income and multiethnic schoolchildren: A diet and physical activity assessment. J Nutr 1997;127:2310-2315.
47. Baldridge AD, Perez-Atayde AR, Graeme-Cook F, Higgins L, Lavine JE. Idiopathic steatohepatitis in childhood: A multicenter retrospective study. J Pediatr 1995;127:700-704.
48. Powell EE, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: A follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74-80.
49. Diehl AM, Goodman Z, Ishak KG. Alcoholic liver disease in nonalcoholics. A clinical and histologic comparison with alcohol-induced liver injury. Gastroenterology 1988;95:1056-1062.
50. Lee RG. Nonalcoholic steatohepatitis: A study of 49 patients. Hum Pathol 1989;20:594-598.
51. Nonomura A, Mizukami Y, Unoura M, Kobayashi K, Takeda Y, Takeda R. Clinicopathologic study of alcohol-like liver disease in non-alcoholics; non-alcoholic steatohepatitis and fibrosis. Gastroenterol Jpn 1992;27:521-528.
52. Lee JH, Doe J. Familial risk ratios for extreme obesity: Implications for mapping human obesity genes. Int J Obes Relat Metab Discord 1997;21:935-940.
53. Trevisan R. The epidemiology of diabetes mellitus. Nephrol Dial Transplant 1998;13(Suppl):2-5.
54. Chagnon YC. Familial aggregation of obesity, candidate genes and quantitative trait loci. Curr Opin Lipidol 1997;8:205-211.
55. Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med 2000;108:9-13.
56. Altman AR, Gottfried EB, Paronetto F, Lieber CS. Idiopathic familial cirrhosis and steatosis in adults. Gastroenterology 1979;77:1211-1216.
57. Castellano G, Garfia C, Gomez-Coronado D, Arenas J, Manzanares J, Colina F, Solis-Herruzo JA. Diffuse fatty liver in familial heterozygous hypobetalipoproteinemia. J Clin Gastroenterol 1997;25:379-382.
58. Ogatta H, Akagi K, Nagamatsu A, Suzuki N, Nomiyama K, Fujishima M. Fatty liver in a case with heterozygous familial hypobetalipoproteinemia. Am J Gastroenterol 1997;92:339-342.
59. Kagimoto T, Higaki T, Nagata K, Morino Y, Takatsuki K. An interesting syndrome of hemolytic anemia, degeneration of the liver and diabetes associated with a high red cell Mg-ATPase, detected by 31P spectroscopy. NMR Biomed 1989;2:93-97.
60. Hsieh SD, Yoshinaga H, Muto T, Sakurai Y. Regular physical activity and coronary risk factors in Japanese men. Circulation 1998;97:661-665.
61. Ikai E, Honda R, Yamada Y. Serum gamma-glutamyl transpeptidase level and blood pressure in nondrinkers: A possible pathogenetic role of fatty liver in obesity-related hypertension. J Hum Hypertens 1994;8:95-100.
62. Maruhama Y, Abe R, Okuguchi F, Olkawa S, Ohneda A, Goto Y. Interactions of obesity and glucose-stimulated insulin secretion in familial hypertriglyceridemia. Oiabetes 1978;27:682-693.
63. Lonardo A. Fatty liver and nonalcoholic steatohepatitis. Where do we stand and where are we going? Dig Dis 1999;17:80-89.
64. Marchesini G, Brizi M, Morselli-Labate AM, Bianchi G, Bugianesi E, McCullough AJ, Forlani G, Melchionda N. Association of non-alcoholic fatty liver disease with insulin resistance. Am J Med 1999;107:450-455.
65. Lyznicki JM, Young DC, Riggs JA, Davis RM; Council on Scientific Affairs, American Medical Association. Obesity: Assessment and management in primary care. Am Fam Physician 2001;63:2185-2196.
66. Ludwig J, McGill DB, Lindor KD. Nonalcoholic steatohepatitis. J Gastroenterol Hepatol 1997;12:398-403.
67. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, Lefebvre PJ. Liver abnormalities in severely obese subjects: Effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-226.
68. Ranlov I, Hardt F. Regression of liver steatosis following gastro plasty or gastric bypass for morbid obesity. Digestion 1990;47:208-214.
69. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995;10:414-421.
70. Eriksson S, Eriksson KF, Bondesson L. Nonalcoholic steatohepatitis in obesity: A reversible condition. Acta Med Scand 1986;220:83-88.
71. Kral JG, Schaffner F, Pierson RN Jr, Wang J. Body fat topography as an independent predictor of fatty liver. Metabolism 1993;42:548-551.
72. Gillum RF, Mussolino ME, Madans JH. Body fat distribution and hypertension incidence in women and men. The NHANES I epidemiologic follow-up study. Int J Obes Relat Metab Disord 1998;22:127-134.
73. Van Steenbergen W, Lanckmans S. Liver disturbances in obesity and diabetes mellitus. Int J Obes Relat Metab Disord 1995;19(Suppl 3):S27-S36.
74. DeFronzo RA, Ferrannini E. Insulin resistance: A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia and atherosclerothic cardiovascular disease. Diabetes Care 1991;14:173-194.
75. Angulo P, Keach JC, Batts KP, Lindor KD. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-1362.
76. Goto T, Onuma T, Takebe K, Kral JG. The influence of fatty liver on insulin clearance and insulin resistance in non-diabetic Japanese subjects. Int J Obes Relat Metab Disord 1995;19:841-845.
77. Inokuchi T, Watanabe K, Kameyama H, Orita M. Altered basal C-peptide/insulin molar ratios in obese patients with fatty liver. Jpn J Med 1988;27:272-276.
78. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK, Luketic VA, Shiffman ML, Clore JN. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-1192.
79. Caldwell SH, Swerdlow RH, Khan EM, Iezzoni JC, Hespenheide EE, Parks JK, Parker WD Jr. Mitochondrial abnormalities in non-alcoholic steatohepatitis. J Hepatol 1999;31:430-434.
80. Weltman MD, Farrell GC, Liddle C. Increased hepatocyte CYP2E1 expression in a rat nutritional model of hepatic steatosis with inflammation. Gastroenterology 1996;111:1645-1653.
81. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: Implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-2562.
82. Partin JS, Partin JC, Schubert WK, McAdams AJ. Liver ultrastructure in abetalipoproteinemia: Evolution of micronodular cirrhosis. Gastroenterology 1974;67:107-118.
83. Powell EE, Searle J, Mortimer R. Steatohepatitis associated with limb lipodystrophy. Gastroenterology 1989;97:1022-1024.
84. Shah SS, Desai HG. Apolipoprotein deficiency and chronic liver disease. J Assoc Phys India 2001;49:274-278.
85. Robertson DA, Wright R, Cirrhosis in partial lipodystrophy. Postgrad Med J 1989;65:318-320.
86. Cauble MS, Gilroy R, Sorrell MF, Mailliard ME, Sudan DL, Anderson JC, Wisecarver JL, Balakrishnan S, Larsen JL. Lipoatrophic diabetes and end-stage liver disease secondary to nonalcoholic steatohepatitis with recurrence after liver transplantation. Transplantation 2001;71:892-895.
87. Wasserman JM, Thung SN, Berman R, Bodenheimer HC Jr, Sigal SH. Hepatic Weber-Christian disease. Semin Liv Dis 2001;21:115-118.
88. Poucell S, Ireton J, Valencia-Mayoral P, Downar E, Larratt L, Patterson J. Amiodarone-associated phospholipidosis and fibrosis of the liver. Light, immunohistochemical and electron microscopic studies. Gastroenterology 1984;86:926-936.
89. Pessayre D, Bichara M, Degott C, Potet F, Benhamou JP, Feldman G. Perhexiline maleate induced cirrhosis. Gastroenterology 1979;76:170-177.
90. Pratt DS, Knox TA, Erban J. Tamoxifen-induced steatohepatitis. Ann Intern Med 1995;123:236.
91. Martinez E, Mocroft A, Garcia-Viejo MA, Perez-Cuevas JB, Blanco JL. Risk of lipodystrophy in HIV-1-infected patients treated with protease inhibitors: A prospective cohort study. Lancet 2001;357:592-598.
92. Kotler DP, Engleson ES. The lowdown on lipodystrophy. Special report from the 2nd international workshop on adverse drug reactions and lipodystrophy. Posit Living 2001;10:5-6.
93. Rakotoambinina B, Medioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1 infected patients receiving triple combination antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr 2001;27:443-449.
94. Herman JS, Easterbrook PJ. The metabolic toxicities of antiretroviral therapies. Int J STD AIDS 2001;12:555-562.
95. Van der valk M, Bisschop PH, Romjin JA, Ackermans MT, Lange JM. Lipodystrophy in HIV-1 positive patients is associated with insulin resistance in multiple metabolic pathways. AIDS 2001;15:2093-2100.
96. Cotrim HP, Andrade ZA, Parana R, Portugal M, Lyra LG, Freitas LA. Nonalcoholic steatohepatitis: A toxic liver disease in industrial workers [see comments]. Liver 1999;19:299-304.
97. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walker NI, Ward PJ, Jazwinska EC, Powell LW. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 1998;114:311-318.
98. Bonkovsky HL, Jawaid Q, Tortorelli K, LeClair P, Cobb J, Lambrecht RW, Banner BF. Non-alcoholic steatohepatitis and iron: Increased prevalence of mutations of the HFE gene in nonalcoholic steatohepatitis. J Hepatol 1999;31:421-429.
99. Younossi ZM, Gramlich T, Bacon BR, Matteoni CA, Boparai N, O'Neill R, McCullough AJ. Hepatic iron and nonalcoholic fatty liver disease. Hepatology 1999;30:847-850.
100. Sonsuz A, Basaranoglu M, Ozbay G. Relationship between aminotransferase levels and histopathological findings in patients with nonalcoholic steatohepatitis (letter). Am J Gastroenterol 2000;95:1370-1371.
101. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-654.
102. Tajiri K, Takenawa H, Yamaoka K, Yamane M, Marumo F, Sato C. Nonalcoholic steatohepatitis masquerading as autoimmune hepatitis. J Clin Gastroenterol 1997;25:538-540.
103. da Silva PM, Eliseu T, Costa MM, Bastos H, Nobre FL. [Nonalcoholic steatohepatitis]. Acta Med Port 1995;8:323-327.
104. Sanson-Fisher R. The measurement of alcohol consumption and alcohol-related problems. Aust Drug Alcohol Rev 1986;5:309-310.
105. Lewis KO, Paton A. Tools of alcohol detection. Br Med J 1981;283:1531-1532.
106. Salaspuro M. Use of enzymes for the diagnosis of alcohol-related organ damage. Enzyme 1987;37:87-107.
107. Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase: A sensitive marker of alcoholism with or without alcoholic hepatitis. Hepatology 1984;4:893-896.
108. Nalpas B, Vassault A, Charpin S, Lacour B, Berthelot P. Serum mitochondrial aspartate aminotransferase as a marker of chronic alcoholism: Diagnostic value and interpretation in a liver unit. Hepatology 1986;6:608-614.
109. Storey E, Anderson GJ, Mack U, Powell LJ, Halliday JW. Desialylated transferrin as a serologic marker of chronic excessive alcohol ingestion. Lancet 1987;1:1292-1294.
110. Fletcher LM, Kwoh Gain I, Powell EE, Powell LW, Halliday JW. Markers of chronic alcohol ingestion in patients with nonalcoholic steatohepatitis: An aid to diagnosis. Hepatology 1991;13:455-459.
111. Nomura F, Ohnishi K, Koen H, Hiyama Y, Nakayama T, Itoh Y, Shirai K, Saitoh Y, Okuda K. Serum cholinesterase in patients with fatty liver. J Clin Gastroenterol 1986;8:599-602.
112. Ong JP, Younossi ZM, Speer C, Olano A, Gramlich T, Boparai N. Chronic hepatitis C and superimposed nonalcoholic fatty liver disease. Liver 2001;21:266-271.
113. Gore RM. Diffuse liver disease. In: Gore RM, Levine MS, Laufer I, eds. Textbook of Gastrointestinal Radiology. Philadelphia: Saunders, 1994:1968-2017.
114. Yajima Y, Ohta K, Narui T, Abe R, Suzuki H, Ohtsuki M. Ultrasonographical diagnosis of fatty liver: Significance of the liver-kidney contrast. Tohoku J Exp Med 1983;139:43-50.
115. Fusamoto H, Suzuki K, Hayashi N, et al. Obesity and liver disease: evaluation of fatty infiltration of the liver using ultrasonic attenuation. J Nutr Sci Vitaminol Tokyo 1991;37(suppl):S71-S77.
116. Kreft B, Tanimoto A, Baba Y, Zhao L, Chen J, Middleton MA, Compton CC, Finn JP, Stark DD. Diagnosis of fatty liver with MR imaging. J Magn Reson Imaging 1992;2:463-471.
117. Yousefzadeh D, Lupetin AR, Jackson JH. The radiographic signs of fatty liver. Radiology 1979;131:351-355.
118. Bydder GM, Chapman RWG, Harry D. Computed tomography attenuation values in fatty liver. Comput Tomograph 1981;5:33-38.
119. Piekarski J, Goldberg HI, Royal SA, Axel L, Moss AA. Difference between liver and spleen CT numbers in the normal adult: Its usefulness in predicting the presence of diffuse liver disease. Radiology 1980;137:727-729.
120. Ducommun JC, Goldberg HI, Korobkin M, Moss AA, Kressel HY. The relation of liver fat to computed tomography numbers: A preliminary experimental study in rabbits. Radiology 1979;130:511-513.
121. Galambos JT. Natural history of alcoholic hepatitis. 3. Histologic changes. Gastroenterology 1972;63:1026-1035.
122. Jacobs JE, Birnbaum BA, Shapiro MA, Langlotz CP, Slosman F, Rubesin SE, Horii SC. Diagnostic criteria for fatty infiltration of the liver on contrast-enhanced helical CT. AJR 1998;171:659-664.
123. Johnston RJ, Stamm ER, Lewin JM, Hendrick RE, Archer PG. Diagnosis of fatty infiltration of the liver on contrast enhanced CT: Limitations of liver-minus-spleen attenuation difference measurements. Abdom Imaging 1998;23:409-415.
124. Mendler MH, Bouillet P, Le Sidaner A, Lavoine E, Labrousse F, Sautereau D, Pillegand B. Dual-energy CT in the diagnosis and quantification of fatty liver: Limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol 1998;28:785-794.
125. Nomura F, Ohnishi K, Ochiai T, Okuda K. Obesity-related nonalcoholic fatty liver: CT features and follow-up studies after lowcalorie diet. Radiology 1987;162:845-847.
126. Outwater EK, Blasbalg R, Siegelman ES, Vala M. Detection of lipid in abdominal tissues with opposed-phase gradient echo images at 1.5 T: Techniques and diagnostic importance. Radiographics 1998;18:1465-1480.
127. Longo R, Pollesello P, Ricci C, Masutti F, Kvam BJ, Bercich L, Croce LS, Grigolato P, Paoletti S, de Bernard B, et al. Proton MR spectroscopy in quantitative in vivo determination of fat content in human steatosis. J Magn Reson Imaging 1995;5:281-285.
128. Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA. Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 1997;15:287-293.
129. Marks DB, Marks AD, Smith CM. Generation of ATP from fatty acids and ketone bodies. In: Marks DB, Marks AD, Smith CM, eds. Basic Medical Biochemistry. Baltimore: Williams and Wilkins, 1996:357-372.
130. Fishbein M, Smith M, Li BU. A rapid MRI technique for the assessment of hepatic steatosis in a subject with mediumchain acyl-coenzyme A dehydrogenase (MCAD) deficiency. J Pediatr Gastroenterol Nutr 1998;27:224-227.
131. Chevallier P, Bahadoran P, Buckley MJ, Hebuterne X, Diaine B, Chevallier A, Coussement A. Hepatic multi-nodular focal fatty metamorphosis in acquired porphyria cutanea tarda. Sonographic, CT, and MRI features. Clin Imaging 1998;22:418-421.
132. Marks SJ, Moore NR, Ryley NG, Clark ML, Pointon JJ, Strauss BJ, Hockaday TD. Measurement of liver fat by MRI and its reduction by dexfenfluramine in NIDDM. Int J Obes Relat Metab Disord 1997;21:274-279.
133. Fishbein MH, Stevens WR. Rapid MRI using a modified Dixon technique: A noninvasive and effective method for detection and monitoring of fatty metamorphosis of the liver. Pediatr Radiol 2001;31:806-809.
134. Van Ness MM, Diehl AM. Is liver biopsy useful in the evaluation of patients with chronically elevated liver enzymes? Ann Intern Med 1989;111:473-478.
135. Sorbi D, McGill DB, Thistle JL, Therneau TM, Henry J, Lindor KD. An assessment of the role of liver biopsies in asymptomatic patients with chronic liver test abnormalities. Am J Gastroenterol 2000;95:3206-3210.
136. Itoh S, Yougel T, Kawagoe K. Comparison between nonalcoholic steatohepatitis and alcoholic hepatitis. Am J Gastroenterol 1987;82:650-654.
137. Sorbi D, Boynton J, Lindor KD. The ratio of aspartate aminotransferase to alanine aminotransferase: Potential value in differentiating nonalcoholic steatohepatitis from alcoholic liver disease. Am J Gastroenterol 1999;94:1018-1022.
138. Pinto HC, Baptista A, Camilo ME, Valente A, Saragoca A, de Moura MC. Nonalcoholic steatohepatitis. Clinicopathological comparison with alcoholic hepatitis in ambulatory and hospitalized patients. Dig Dis Sci 1996;41:172-179.
139. Braillon A, Capron JP, Herve MA, Degott C, Quenum C. Liver in obesity. Gut 1985;26:133-139.
140. Iturriaga H, Bunout D, Hirsch S, Ugarte G. Overweight as a risk factor or a predictive sign of histological liver damage in alcoholics. Am J Clin Nutr 1988;47:235-238.
141. Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-669.
142. Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: A case-control study. Hepatology 2000;32:689-692.
143. Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl 2001;7:363-373.
144. Drenick EJ, Fisler J, Johnson D. Hepatic steatosis after intestinal bypass - Prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition. Gastroenterology 1982;82:535-548.
145. Drenick EJ, Simmons F, Murphy J. Effect on hepatic morphology of treatment of obesity by fasting, reducing diets and small bowel bypass. N Engl J Med 1970;282:829-834.
146. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: Predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
147. Adler M, Schaffner F. Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 1979;67:811-816.
148. Laurin J, Lindor KD, Crippin JS, Gossard A, Gores GJ, Ludwig J. Ursodeoxycholic acid or clofibrate in the treatment of non-alcohol induced steatohepatitis: A pilot study. Hepatology 1996;23:1464-1467.
149. Hilden M, Juhl E, Thomen AC, Christoffersen P. Fatty liver persisting for up to 33 years. Acta Med Scand 1973;194:485-489.
150. Propst A, Propst T, Judmaier G, Vogel W. Prognosis in nonalcoholic steatohepatitis (letter). Gastroenterology 1995;108:1607.
151. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, Torimura T, Inuzuka S, Sata M, Tanikawa K. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-107.
152. Vajro P, Fontanella A, Perna C, Orso G, Tedesco M, De Vincenzo A. Persistent hyperaminotransferasemia resolving after weight reduction in obese children [see comments]. J Pediatr 1994;125:239-241.
153. Dean RH, Scott HW Jr, Shull HJ, Gluck FW. Morbid obesity: Problems associated with operative management. Am J Clin Nutr 1977;30:90-97.
154. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-229.
155. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000;30:48-53.
156. Ogden CL, Troiano RP, Briefel RR, Kuczmarski RJ, Flegal KM, Johnson CL. Prevalence of overweight among preschool children in the United States, 1971 through 1994. Pediatrics 1997;99:E1.
157. Rosner B, Prineas R, Loggie J, Daniels SR. Percentiles for body mass index in U.S. children 5 to 17 years of age [see comments]. J Pediatr 1998;132:211-222.
158. Moran JR, Ghishan FK, Halter SA, Greene HL. Steatohepatitis in obese children: A cause of chronic liver dysfunction. Am J Gastroenterol 1983;78:374-377.
159. Snodgrass PJ. Obesity, small-bowel bypass and liver disease. N Engl J Med 1970;282:870-871.
160. Kern WH, Heger AH, Payne JH, Dewind LT. Fatty metamorphosis of the liver in morbid obesity. Arch Pathol 1973;96:342-346.
161. Kern WH, Payne JH, Dewind LT. Hepatic changes after smallintestinal bypass for morbid obesity. Am J Clin Pathol 1974;61:763-768.
162. Salmon PA, Reedyk L. Fatty metamorphosis in patients with jejunoileal bypass. Surg Gynecol Obstet 1975;141:75-84.
163. Petersen P. Fatty liver in patients with moderate alcohol consumption, diabetes mellitus and overweight. Scand J Gastroenterol 1977;12:781-784.
164. Manes JL, Taylor HB, Starkloff GB. Relationship between hepatic morphology and clinical and biochemical findings in morbidly obese patients. J Clin Pathol 1973;26:776-783.
165. White JJ, Moxley RT III, Pozefsky T, Lockwood DH. Transient kwaskiorkor: A cause of fatty liver following small bowel bypass. Surgery 1974;75:829-840.
166. Halloran LG, Hutcher NE, Levinson SA, Schatzki PF, Hume DM. Morphology of the liver before and after intestinal bypass for morbid obesity. Surg Forum 1974;25:359-361.
167. Marubbio AT, Jr., Buchwald H, Schwartz MZ, Varco R. Hepatic lesions of central pericellular fibrosis in morbid obesity, and after jejunoileal bypass. Am J Clin Pathol 1976;66:684-691.
168. Baddeley RM. Results of jejuno-ileostomy for gross refractory obesity. Br J Surg 1976;63:801-806.
169. Nasrallah SM, Wills CE Jr, Galambos JT. Liver injury following jejunoileal bypass. Are there markers? Ann Surg 1980;192:726-729.
170. Heimburger SL, Steiger E, Lo Gerfo P, Biehl AG, Williams MJ. Reversal of severe fatty hepatic infiltration after intestinal bypass for morbid obesity by calorie-free amino acid infusion. Am J Surg 1975;129:229-235.
171. Griffen WO Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977;186:500-509.
172. Buckwalter JA. Clinical trial of jejunoileal and gastric bypass for the treatment of morbid obesity: Four-year progress report. Am Surg 1980;46:377-381.
173. Luyckx FH, Scheen AJ, Desaive C, Thiry A, Lefebvre PJ. Parallel reversibility of biological markers of the metabolic syndrome and liver steatosis after gastroplasty-induced weight loss in severe obesity (letter). J Clin Endocrinol Metab 1999;84:4293.
174. Lieverse RJ, Jansen JB, Masclee AA, Lamers CB. Gastrointestinal disturbances with obesity. Scand J Gastroenterol Suppl 1993;200:53-58.
175. Nomura H, Kashiwagi S, Hayashi J, Kajiyama W, Ikematsu H, Noguchi A, Tani S, Goto M. Prevalence of gallstone disease in a general population of Okinawa, Japan [see comments]. Am J Epidemiol 1988;128:598-605.
176. Araujo LM, De Oliveira DA, Nunes DS. Liver and biliary ultrasonography in diabetic and non-diabetic obese women. Diabetes Metab 1998;24:458-462.
177. Moore SJ, Auchterlonie IA, Cole GF, Gray ES, Dean JC. Partial lipodystrophy presenting with myopathy. Dev Med Child Neurol 1999;41:127-131.
178. Hubler A, Abendroth K, Keiner T, Stocker W, Kauf E, Hein G, Stein G. Dysregulation of insulin-like growth factors in a case of generalized acquired lipoatrophic diabetes mellitus (Lawrence Syndrome) connected with autoantibodies against adipocyte membranes. Exp Clin Endocrinol Diabetes 1998;106:79-84.
179. Ursich MJ, Fukui RT, Galvao MS, Marcondes JA, Santomauro AT, Silva ME, Rocha DM, Wajchenberg BL. Insulin resistance in limb and trunk partial lipodystrophy (type 2 Kobberling-Dunnigan syndrome). Metabolism 1997;46:159-163.
180. Hourigan LF, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology 1999;29:1215-1219.
181. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-1364.
182. Rubbia-Brandt L, Quadri R, Abid K, Giostra E, Male PJ, Mentha G, Spahr L, Zarski JP, Borisch B, Hadengue A, Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol 2000;33:106-115.
183. Rubbia-Brandt L, Leandro G, Spahr L, Giostra E, Quadri R, Male PJ, Negro F. Liver steatosis in chronic hepatitis C: A morphological sign suggesting infection with HCV genotype 3. Histopathology 2001;39:119-124.
184. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 1997;78:1527-1531.
185. Fujie H, Yotsuyanagi H, Moriya K, Shintani Y, Tsutsumi T, Takayama T, Makuuchi M, Matsuura Y, Miyamura T, Kimura S, Koike K. Steatosis and intrahepatic hepatitis C virus in chronic hepatitis. J Med Virol 1999;59:141-145.
186. Fernandez-Miranda C, Castellano G, Guijarro C, Fernandez I, Schoebel N, Larumbe S, Gomez-Izquierdo T, del Palacio A. Lipoprotein changes in patients with hepatitis C treated with interferon alpha. Am J Gastroenterol 1998;93:1901-1904.
187. Alexandropoulos EC, Kontochristopoulos GJ, Zakapoulou N. Hypertriglyceridemia during low-dose interferon alpha-2b treatment in a patient with Kaposi's sarcoma. Dermatology 2001;202:344-345.
188. Garcia Urena MA, Colina Ruiz-Delgado F, Moreno Gonzalez E, Jimenez Romero C, Garcia Garcia I, Loinzaz Segurola C, Gonzalez-Pinto, Gomez Sanz R.
189. Broughan TA, Douzdjian V. Donor liver selection. The South Eastern Organ Procurement Foundation Liver Committee. Am Surg 1998;64:785-790.
190. Fukumori T, Ohkohchi N, Tsukamoto S, Satomi S. Why is fatty liver unsuitable for transplantation? Deterioration of mitochondrial ATP synthesis and sinusoidal structure during cold preservation of a liver with steatosis. Transplant Proc 1997;29:412-415.
191. Gao W, Connor HD, Lemasters JJ, Mason RP, Thurman RG. Primary nonfunction of fatty livers produced by alcohol is associated with a new antioxidant insensitive free radical species. Transplantation 1995;59:674-679.
192. Fishbein TM, Fiel MI, Emre S, Cubukcu O, Guy SR, Schwartz ME, Miller CM, Sheiner PA. Use of livers with microvesicular fat safely expands the donor pool. Transplantation 1997;64:248-251.
193. McCaughan GW. Recurrence of nonalcoholic steatohepatitis (NASH) post-liver transplantation (letter). Liver Transpl Surg 1997;3:683.
194. Molloy RM, Komorowski R, Varma RR. Recurrent nonalcoholic steatohepatitis and cirrhosis after liver transplantation. Liver Transpl Surg 1997;3:177-178.
195. Carson K, Washington MK, Treem WR, Clavien PA, Hunt CM. Recurrence of nonalcoholic steatohepatitis in a liver transplant recipient. Liver Transpl Surg 1997;3:174-176.
196. Kim WR, Poterucha JJ, Porayko MK, Dickson ER, Steers JL, Wiesner RH. Recurrence of nonalcoholic steatohepatitis following liver transplantation. Transplantation 1996;62:1802-1805.
197. D'Sauza-Gburek SM, Batts KP, Nikias GA, Weisner RH, Krom RAF. Liver transplantation for jejunoileal bypass-associated cirrhosis. Liver Transpl Surg 1997;3:23-27.
198. Palmer M, Schaffner F, Thung SN. Excessive weight gain after liver transplantation. Transplantation 1991;51:797-800.
199. Saadeh S, Younossi ZM. The spectrum of nonalcoholic fatty liver disease: From steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med 2000;67:96-97, 101-104.
200. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-1413.
201. Anonymous. Executive summary of the clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults. Arch Intern Med 1998;158:1855-1867.
202. Barlow SE, Dietz WH. Obesity evaluation and treatment: Expert committee recommendations. The Maternal and Child Health Bureau, Health Resources and Services Administration and the Department of Health and Human Services. Pediatrics 1998;102:E29.
203. Hermansen K. Diet, blood pressure and hypertension. Br J Nutr 2000;83(Suppl 1):S113-S119.
204. Sothern MS, Loftin JM, Udall JN, Suskind RM, Ewing TL, Tang SC, Blecker U. Safety, feasibility, and efficacy of a resistance training program in preadolescent obese children. Am J Med Sci 2000;319:370-375.
205. Tremblay A, Doucet E, Imbeault P. Physical activity and weight maintenance. Int J Obes Relat Metab Disord 1999;23(suppl 3):S50-S54.
206. Niskanen L, Uusitupa M, Sarlund H, Siitonen O, Paljarvi L, Laakso M. The effects of weight loss on insulin sensitivity, skeletal muscle composition and capillary density in obese non-diabetic subjects. Int J Obes Relat Metab Disord 1996;20:154-160.
207. Lean ME. Is long-term weight loss possible? Br J Nutr 2000;83(Suppl 1):S103-S111.
208. Balkestein EJ, van Aggel-Leijssen DP, van Baak MA, Struijker-Boudier HA, Van Bortel LM. The effect of weight loss with or without exercise training on large artery compliance in healthy obese men. J Hypertens 1999;17:1831-1835.
209. Weinsier RL, Wilson LJ, Lee J. Medically safe rate of weight loss for the treatment of obesity: A guideline based on risk of gallstone formation. Am J Med 1995;98:115-117.
210. Shiffman ML, Kaplan GD, Brinkman-Kaplan V, Vickers FF. Prophylaxis against gallstone formation with ursodeoxycholic acid in patients participating in a very-low-calorie diet program. Ann Intern Med 1995;122:899-905.
211. Sugerman HJ, Brewer WH, Shiffman ML, Brolin RE, Fobi MA, Linner JH, MacDonald KG, MacGregor AM, Martin LF, OramSmith JC, et al. A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg 1995;169:91-96: discussion 96-97.
212. Worobetz LJ, Inglis FG, Shaffer EA. The effect of ursodeoxycholic acid therapy on gallstone formation in the morbidly obese during rapid weight loss. Am J Gastroenterol 1993;88:1705-1710.
213. Broomfield PH, Chopra R, Sheinbaum RC, Bonorris GG, Silverman A, Schoenfield LJ, Marks JW. Effects of ursodeoxycholic acid and aspirin on the formation of lithogenic bile and gallstones during loss of weight. N Engl J Med 1988;319:1567-1572.
214. Shoheiber O, Biskuplak JE, Nash DB. Estimation of the cost savings resulting from the use of ursodiol for the prevention of gallstones in obese patients undergoing rapid weight reduction. Int J Obes Relat Metab Disord 1997;21:1038-1045.
215. Anonymous. Weight cycling. National Task Force on the Prevention and Treatment of Obesity. JAMA 1994;272:1196-1202.
216. Harris RB, Kor H. Insulin insensitivity is rapidly reversed in rats by reducing dietary fat from 40 to 30% of energy. J Nutr 1992;122:1811-1822.
217. Silberbauer CJ, Jacober B, Langhans W. Dietary fat level and short-term effects of a high-fat meal on food intake and metabolism. Ann Nutr Metab 1998;42:75-89.
218. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ, Kraegen EW. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997;46:1768-1774.
219. Hallfrisch J, Facn, Behall KM. Mechanisms of the effects of grains on insulin and glucose responses. J Am Coll Nutr 2000;19:320S-325S.
220. Song YJ, Sawamura M, Ikeda K, Igawa S, Yamori Y. Soluble dietary fibre improves insulin sensitivity by increasing muscle GLUT-4 content in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 2000;27:41-45.
221. Luo J, Rizkalla SW, Boillot J, Alamowitch C, Chaib H, Bruzzo F, Desplanque N, Dalix AM, Durand G, Slama G. Dietary (n-3) polyunsaturated fatty acids improve adipocyte insulin action and glucose metabolism in insulin-resistant rats: relation to membrane fatty acids. J Nutr 1996;126:1951-1958.
222. Clarke SD, Baillie R, Jump DB, Nakamura MT. Fatty acid regulation of gene expression. Its role in fuel partitioning and insulin resistance. Ann N Y Acad Sci 1997;827:178-187.
223. Montagne O, Vedel I, Durand-Zaleski I. Assessment of the impact of fibrates and diet on survival and their cost-effectiveness: Evidence from randomized, controlled trials in coronary heart disease and health economic evaluations. Clin Ther 1999;21:2027-2035.
224. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW Jr, Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson K, Wylie-Rosett J, St Jeor S, Suttie J, Tribble DL, Bazzarre TL. AHA dietary guidelines: Revision 2000. A statement for healthcare professionals from the nutrition committee of the American Heart Association. Stroke 2000;31:2751-2766.
225. Clark MJ Jr, Sterrett JJ, Carson DS. Diabetes guidelines: A summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin Ther 2000;22:899-910; discussion 898.
226. Miller WC, Koceja DM, Hamilton EJ. A meta-analysis of the past 25 years of weight loss research using diet, exercise or diet plus exercise intervention. Int J Obes Relat Metab Disord 1997;21:941-947.
227. Dattilo AM, Kris-Etherton PM. Effects of weight reduction on blood lipids and lipoproteins: A meta-analysis. Am J Clin Nutr 1992;56:320-328.
228. Stern JS, Hirsch J, Blair SN, Foreyt JP, Frank A, Kumanyika SK, Madans JH, Marlatt GA, St Jeor ST, Stunkard AJ. Weighing the options: Criteria for evaluating weight-management programs. The Committee to Develop Criteria for Evaluating the Outcomes of Approaches to Prevent and Treat Obesity. Obes Res 1995;3:591-604.
229. Howell WH, McNamara DJ, Tosca MA, Smith BT, Gaines JA. Plasma lipid and lipoprotein responses to dietary fat and cholesterol: A meta-analysis. Am J Clin Nutr 1997;65:1747-1764.
230. Brown SA, Upchurch S, Anding R, Winter M, Ramirez G. Promoting weight loss in type II diabetes. Diabetes Care 1996;19:613-624.
231. Tang JL, Armitage JM, Lancaster T, Silagy CA, Fowler GH, Neil HA. Systematic review of dietary intervention trials to lower blood total cholesterol in free-living subjects. BMJ 1998;316:1213-1220.
232. Kirsch I. Hypnotic enhancement of cognitive-behavioral weight loss treatments - Another meta-reanalysis. J Consult Clin Psychol 1996;64:517-519.
233. Allison DB, Faith MS. Hypnosis as an adjunct to cognitivebehavioral psychotherapy for obesity: A meta-analytic reappraisal. J Consult Clin Psychol 1996;64:513-516.
234. Petrides AS, Matthews DE, Esser U. Effect of moderate exercise on insulin sensitivity and substrate metabolism during post-exercise recovery in cirrhosis. Hepatology 1997;26:972-979.
235. Fogelholm M, Kukkonen-Harjula K, Nenonen A, Pasanen M. Effects of walking training on weight maintenance after a verylow-energy diet in premenopausal obese women: A randomized controlled trial. Arch Intern Med 2000;160:2177-2184.
236. Ross R, Dagnone D, Jones PJ, Smith H, Paddags A, Hudson R, Janssen I. Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 2000;133:92-103.
237. Blumenthal JA, Sherwood A, Gullette EC, Babyak M, Waugh R, Georgiades A, Craighead LW, Tweedy D, Feinglos M, Appelbaum M, Hayano J, Hinderliter A. Exercise and weight loss reduce blood pressure in men and women with mild hypertension: Effects on cardiovascular, metabolic, and hemodynamic functioning. Arch Intern Med 2000;160:1947-1958.
238. Donnelly JE, Jacobsen DJ, Heelan KS, Seip R, Smith S. The effects of 18 months of intermittent vs. continuous exercise on aerobic capacity, body weight and composition, and metabolic fitness in previously sedentary, moderately obese females. Int J Obes Relat Metab Disord 2000;24:566-572.
239. Andersen RE, Wadden TA, Bartlett SJ, Zemel B, Verde TJ, Franckowiak SC. Effects of lifestyle activity vs structured aerobic exercise in obese women: A randomized trial [see comments]. JAMA 1999;281:335-340.
240. Weinstock RS, Dai H, Wadden TA. Diet and exercise in the treatment of obesity: Effects of 3 interventions on insulin resistance. Arch Intern Med 1998;158:2477-2483.
241. Bylund AC, Bjuro T, Cederblad G, Holm J, Lundholm K, Sjostroom M, Angquist KA, Schersten T. Physical training in man. Skeletal muscle metabolism in relation to muscle morphology and running ability. Eur J Appl Physiol 1977;36:151-169.
242. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: A reexamination. Diabetes 2000;49:677-683.
243. Kang J, Robertson RJ, Hagberg JM, Kelley DE, Goss FL, DaSilva SG, Suminski RR, Utter AC. Effect of exercise intensity on glucose and insulin metabolism in obese individuals and obese NIDDM patients. Diabetes Care 1996;19:341-349.
244. Stefanick ML. Physical activity for preventing and treating obesity-related dyslipoproteinemias. Med Sci Sports Exerc 1999;31:S609-S618.
245. Eriksson J, Tuominen J, Valle T, Sundberg S, Sovijarvi A, Lindholm H, Tuomilehto J, Koivisto V. Aerobic endurance exercise or circuit-type resistance training for individuals with impaired glucose tolerance? Horm Metab Res 1998;30:37-41.
246. Newell SA, Bowman JA, Cockburn JD. Can compliance with nonpharmacologic treatments for cardiovascular disease be improved? Am J Prev Med 2000;18:253-261.
247. Jakicic JM, Winters C, Lang W, Wing RR. Effects of intermittent exercise and use of home exercise equipment on adherence, weight loss, and fitness in overweight women: A randomized trial. JAMA 1999;282:1554-1560.
248. Yanovsky SZ, Yanovsky JA. Obesity. N Engl J Med 2002;346:591-602.
249. Allison TG, Squires RW, Johnson BD, Gau GT. Achieving National Cholesterol Education Program goals for low-density lipoprotein cholesterol in cardiac patients: Importance of diet, exercise, weight control, and drug therapy. Mayo Clin Proc 1999;74:466-473.
250. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord 2000;24:144-150.
251. Apfelbaum M, Vague P, Ziegler O, Hanotin C, Thomas F, Leutenegger E. Long-term maintenance of weight loss after a very-low-calorie diet: A randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med 1999;106:179-184.
252. Cordero-MacIntyre ZR, Peters W, Libanati CR, Espana RC, Howell WH, Lohman TG. Effect of a weight-reduction program on total and regional body composition in obese postmenopausal women. Ann N Y Acad Sci 2000;904:526-535.
253. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish Multimorbidity Study. J Intern Med 2000;248:245-254.
254. Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjostrom L. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000;160:1321-1326.
255. Hauptman J, Lucas C, Boldrin MN, Collins H, Segal KR. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9:160-167.
256. Hall JC, Watts JM, O'Brien PE, Dunstan RE, Walsh JF, Slavotinek AH, Elmslie RG. Gastric surgery for morbid obesity. The Adelaide Study. Ann Surg 1990;211:419-427.
257. Naslund I. Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl 1987;536:1-60.
258. Sugerman HJ, Wolper JL. Failed gastroplasty for morbid obesity. Revised gastroplasty versus Roux-Y gastric bypass. Am J Surg 1984;148:331-336.
259. Pories WJ, Flickinger EG, Meelheim D, Van Rij AM, Thomas FT. The effectiveness of gastric bypass over gastric partition in morbid obesity: Consequence of distal gastric and duodenal exclusion. Ann Surg 1982;196:389-399.
260. Laws HL, Piantadosi S. Superior gastric reduction procedure for morbid obesity: A prospective, randomized trial. Ann Surg 1981;193:334-340.
261. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg 1987;205:613-624.
262. Griffen WO, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977;186:500-509.
263. Manco M, Mingrone G, Greco AV, Capristo E, Gniuli D, De Gaetano A, Gasbarrini G. Insulin resistance directly correlates with increased saturated fatty acids in skeletal muscle triglycerides. Metabolism 2000;49:220-224.
264. Kelley DE, Goodpaster B, Wing RR, Simoneau JA. Skeletal muscle fatty acid metabolism in association with insulin resistance, obesity, and weight loss. Am J Physiol 1999;277:E1130-E1141.
265. Arslanian S, Suprasongsin C. Glucose-fatty acid interactions in prepubertal and pubertal children: Effects of lipid infusion. Am J Physiol 1997;272:E523-E529.
266. Mingrone G, DeGaetano A, Greco AV, Capristo E, Benedetti G, Castagneto M, Gasbarrini G. Reversibility of insulin resistance in obese diabetic patients: Role of plasma lipids. Diabetologia 1997;40:599-605.
267. Randle PJ, Garland PB, Hales CN, Newsholme EA. The glucosefatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus. Lancet 1963;1:785-789.
268. Rashid A, Wu TC, Huang CC, Chen CH, Lin HZ, Yang SQ, Lee FY, Diehl AM. Mitochondrial proteins that regulate apoptosis and necrosis are induced in mouse fatty liver. Hepatology 1999;29:1131-1138.
269. Simoneau JA, Kelley DE, Neverova M, Warden CH. Overexpression of muscle uncoupling protein 2 content in human obesity associates with reduced skeletal muscle lipid utilization. FASEB J 1998;12:1739-1745.
270. Lin HZ, Yang SQ, Chuckaree C, Kuhajda F, Ronnet G, Diehl AM. Metformin reverses fatty liver disease in obese, leptin-deficient mice. Nat Med 2000;6:998-1003.
271. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Zoli M, Melchionda N. Metformin in nonalcoholic steatohepatitis. Lancet 2001;358:893-894.
272. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am J Gastroenterol 2001;96:519-525.
273. Arioglu E, Duncan-Morin J, Sebring N, Rother KI, Gottlieb N, Lieberman J, Herion D, Kleiner DE, Reynolds J, Premkumar A, Sumner AE, Hoofnagle J, Reitman ML, Taylor SI. Efficacy and safety of troglitazone in the treatment of lipodystrophy syndromes [see comments]. Ann Intern Med 2000;133:263-274.
274. Ide T, Nakazawa T, Mochizuki T, Murakami K. Tissue-specific actions of antidiabetic thiazolidinediones on the reduced fatty acid oxidation in skeletal muscle and liver of Zucker diabetic fatty rats. Metabolism 2000;49:521-525.
275. Basaranoglu M, Acbay O, Sonsuz A. A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis (letter). J Hepatol 1999;31:384.
276. Lavine JE. Vitamin E treatment of nonalcoholic steatohepatitis in children: A pilot study [see comments]. J Pediatr 2000;136:734-738.
277. Obinata K, Maruyama T, Hayashi M, Watanabe T, Nittono H. Effect of taurine on the fatty liver of children with simple obesity. Adv Exp Med Biol 1996;403:607-613.
278. Abdelmalek MF, Angulo P, Jorgenson RA, Sylvestre PB, Lindor KD. Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: A pilot study. Am J Gastroenterol 2001;96:2711-2717.
279. Miglio F, Rovati LC, Santoro A, Setnikar I. Efficacy and safety of oral betaine glucuronate in nonalcoholic steatohepatitis. A doubleblind, randomized, parallel-group, placebo-controlled prospective clinical study. Arzneimittelforschung 2000;50:722-727.
280. Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, Larranaga E, Moreno-Otero R. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol 2000;33:716-724.